Precision BioSciences, Inc. announced on February 19, 2025, initial results from the first administration of PBGENE-HBV in cohort 1, the lowest dose level of the ELIMINATE-B trial. PBGENE-HBV was safe and well tolerated in all three participants after the first administration of a 0.2 mg/kg dose.
None of the three participants experienced a Grade ≥2 treatment-related adverse event or serious adverse event. This safety profile is consistent with extensive preclinical safety experiments and mRNA optimization conducted by Precision BioSciences.
In addition to safety, PBGENE-HBV demonstrated a substantial reduction in Hepatitis B surface antigen (HBsAg) in two of the three participants following the first administration. The ELIMINATE-B study is currently enrolling patients in Moldova, Hong Kong, and New Zealand, with plans for additional administrations and dose escalation to define optimal dosing for eliminating cccDNA and inactivating integrated HBV DNA.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.